Replies to post #123977 on Biotech Values

[acgood]

I agree- BLRX looks intriguing and I will be doing further research on this one. Looks like they reacquired the rights to the lead candidate from Cypress after the Cypress activist shareholder/Royalty Pharma buyout (less than a year after signing license deal with BioLineRx)

[genisi]

Teva has 9.6% in Bioline and is the biggest among the controlling shareholders. Teva's strong man - Dr. Schwartz is the Chairman of the BOD and is quite active. On valuation: in general, local market usually gives low valuation to biotech comp. MC was a lot higher before Bioline announced partnering BL-1020. Investors here were very disappointed and the elevated risk plus the need to raise more cash is holding the stock.